Navigation Links
Cost of glaucoma medications may impact treatment
Date:12/27/2007

Philadelphia, December 28, 2007 In the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total. In an article published in the January 2008 issue of the American Journal of Ophthalmology, researchers from The Texas A&M University System Health Science Center College of Medicine, Temple, Texas; analyzed the economics of medically managing glaucoma. The yearly costs to patients of various topical glaucoma medications were calculated and significant price differences and increases in cost over time were found.

The researchers looked at four classes of pharmaceuticals; -blockers, prostaglandins, α2-agonists and carbonic anhydrase inhibitors. They compared both brand-name and generic formulations, evaluated how accurately the bottles were filled and how accurately the medications could be dispensed by patients. Using results from earlier studies, the increases in Average Wholesale Prices (AWP) were also evaluated from 1999 through 2006.

Nonselective -blockers remain the most inexpensive class of glaucoma medications. For all categories of drugs, calculated yearly cost ranged from $150.81 for generic timolol maleate 0.5% (-blocker), to $697.42 for Cosopt (combination formulation), to as high as $873.98 for a three-times-daily dose of Alphagan P 0.15% (α2-agonist). Among brand name -blockers, yearly cost ranged between $203.47 for Timoptic 0.5% and $657.24 for Betoptic S. Generic -blockers consistently were more economical than their brand-name counterparts. Yearly cost of prostaglandin analogs ranged from $427.69 for Travatan to $577.62 for Lumigan. The two carbonic anhydrase inhibitors, Azopt and Trusopt, yielded similar economic profiles. The generic selective α2-agonist brimonidine tartrate 0.2% costs approximately $352.89 and $529.34 per year for the respective two and three drops daily per eye regimens.

AWP trends through two periods, 1999 to 2006 and 2002 to 2006, showed significant increases, even within a category. For example, in the -blockers, Betoptic S increased nearly 100 % from 1999 to 2006, while Timoptic, increased only 11.7 %. In the period 2002 to 2006, the AWP of Timoptic remained constant.

Writing in the article, Steven D. Vold states, Physicians consider many factors when treating patients with glaucoma. Ultimately, the goal of eye care providers is to give the best, most cost-effective care to their patients. Our study addresses the calculated cost per year passed on to the patient for single medication treatment plansAs newer medications and treatment schemes are introduced, future studies will be needed to update the rapidly changing economic information pertaining to the medical management of glaucoma.


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3671
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Glaucoma surgery in the blink of an eye
3. Glaucoma surgery in the blink of an eye
4. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
5. Looking at Glaucoma as a Systemic Disease
6. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
7. Diet and medications may assist prevention of prostate cancer
8. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
9. Patients cant recall their medications to tell doctors
10. The American Pharmacists Association Supports Consumer Education About OTC Medications
11. Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors ... Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, ... risk while tailoring optimized benefit packages that strengthen the relationship between employer and ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology: